Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2019 / Articles / Jul / The Road to Interoperability
Business & Regulation Supply Chain Packaging Technology and Equipment Digital Technologies Packaging Facilities & Equipment Technology & Manufacturing

The Road to Interoperability

The FDA has accepted TraceLink's blockchain and digital recall project into its DSCSA Pilot Program

By Maryam Mahdi 07/18/2019 0 min read Quick Read (pre 2022)

Share

TraceLink has been approved to join the FDA’s Pilot Project Program, which aims to support drug supply stakeholders, including the FDA, in developing interoperable electronic systems capable of tracing Rx drugs through their distribution. Projects will begin in August 2019, and the FDA plans to publish a report based on the findings to help solve challenges associated with the current pharmaceutical supply chain and protect consumers against counterfeit medications. 

TraceLink entered a submission focused on two workstreams: an interoperable blockchain network solution called Trace Histories, and digital recalls. Both are intended to bring together companies from across the pharmaceutical supply chain.

“We are interested in the power of blockchain because of its ability to provide secure, immutable methods of information sharing across the industry. The Trace Histories workstream will explore the validity of using blockchain technology in a revolutionary way, which enables participants to post and share necessary compliance information on the blockchain while simultaneously safeguarding confidential business information.” explains Paul Cianciolo, Senior Vice President, Business Management at Tracelink. 

The second workstream focuses on digital recalls. “Recall verification and notification is a notoriously challenging issue across the pharma and healthcare industries,“ says Cianciolo. “The lack of granularity (scale of detail in a dataset) associated with the products in a supply chain, the existence of information silos and the absence of a dedicated network to distribute recall events all contribute to the inefficiency of the recall process.”

In other words, a recall from a pharmaceutical manufacturer may currently have difficulty reaching the hospitals, pharmacies and patients in possession of affected products.

The digital recalls workstream will evaluate effective methods of data exchange and coordinate with industry stakeholders to prevent recalled products from reaching patients. 

“Combining insights from these leading companies with TraceLink’s digital supply network and solutions will garner compelling information that will contribute to the innovation, security, and interoperability of the supply chain.”

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Maryam Mahdi

After finishing my degree, I envisioned a career in science communications. However, life took an unexpected turn and I ended up teaching abroad. Though the experience was amazing and I learned a great deal from it, I jumped at the opportunity to work for Texere. I'm excited to see where this new journey takes me!

More Articles by Maryam Mahdi

False

Advertisement

Recommended

False

Related Content

Trump Speech Suggests Pharma Tariffs Incoming
Standards & Regulation Supply Chain Business Practice
Trump Speech Suggests Pharma Tariffs Incoming

April 9, 2025

2 min read

US President threatens “major tariff” on pharmaceuticals.

The UK's Radiopharma Revolution
Supply Chain
The UK's Radiopharma Revolution

March 5, 2025

6 min read

Radiopharmaceuticals are a promising approach to cancer, but some countries, including the UK, are lagging behind. A collaboration hopes to change that.

Resilient Supply Chains in an Uncertain World; View From a CDMO
Contract Development Services Business Practice Supply Chain
Resilient Supply Chains in an Uncertain World; View From a CDMO

March 10, 2025

3 min read

From geopolitical conflicts to cyber threats, CDMOs must rethink resilience.

The Role of the Robot
Technology and Equipment Process Control Supply Chain
The Role of the Robot

March 17, 2025

3 min read

From cybersecurity challenges and AI-driven decision-making, to making mundane tasks more skillful, robotics is reshaping pharmaceutical operations.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.